Tirzepatide Mechanism: How Dual GIP and GLP-1 Receptor Activity Works

Tirzepatide is a single engineered peptide that activates both the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). Calling it a dual agonist describes two receptor targets, not two drugs combined. Laboratory studies also show that its activity is not evenly balanced between those targets, which makes the mechanism more nuanced than the name suggests.

At a glance

• Tirzepatide is one 39-amino-acid peptide with activity at both GIP and GLP-1 receptors.
• Its sequence is GIP-based and includes modifications that resist enzymatic cleavage and extend circulation time.
• Receptor studies describe stronger relative engagement of GIPR and biased signalling at GLP-1R.
• Randomized trials establish clinical outcomes, but they do not isolate the exact contribution of each receptor.
• Evidence from an approved tirzepatide medicine does not verify the quality of separately sold research material.

One molecule, two receptor targets

GIP and GLP-1 are incretin hormones that signal through distinct G-protein-coupled receptors. Both pathways can influence glucose-dependent insulin secretion, while their effects across the pancreas, brain, gastrointestinal tract, and other tissues are not identical. Tirzepatide was designed to place activity at both receptors into one peptide.

The original discovery paper described LY3298176, later named tirzepatide, as a 39-amino-acid peptide derived from a GIP sequence with added GLP-1 receptor activity. This matters because the molecule is not simply a GLP-1 agonist with a second label attached; its sequence and receptor profile were engineered together.

How the peptide was engineered

Regulatory product information identifies several structural features that change how the peptide behaves. Tirzepatide contains alpha-aminoisobutyric acid substitutions that help protect against dipeptidyl peptidase-4 cleavage, a C-terminal amide, and a C20 fatty diacid linked through a spacer to lysine at position 20.

The fatty diacid promotes albumin binding and slows clearance. That pharmacokinetic design supports prolonged exposure, but it is separate from receptor selectivity: one set of modifications affects how long the molecule remains available, while the amino-acid sequence determines much of its receptor pharmacology.

What 'imbalanced and biased' means

A detailed receptor study found greater predicted engagement of GIPR than GLP-1R. At GIPR, tirzepatide behaved similarly to native GIP in the assays used. At GLP-1R, it favoured cyclic AMP signalling over beta-arrestin recruitment and produced less receptor internalization than native GLP-1.

These are laboratory pharmacology findings. Terms such as imbalance and signalling bias describe patterns measured in receptor systems and isolated cells; they do not, by themselves, prove why a particular clinical outcome occurs. The authors proposed that this profile may contribute to the molecule's effects, but the relative importance of each pathway remains an active research question.

What human trials add

Large randomized trials provide a different layer of evidence. SURPASS-2 compared tirzepatide with semaglutide in adults with type 2 diabetes, while SURMOUNT-1 studied adults with obesity or overweight plus a weight-related condition. Both reported substantial changes in their prespecified metabolic and body-weight outcomes.

Those trials establish outcomes for the regulated medicine under defined protocols. They do not directly separate the GIP component from the GLP-1 component, and they cannot determine whether receptor balance, signalling bias, exposure duration, or the interaction of all three best explains the observed results.

Evidence boundaries and regulatory context

Health Canada's Drug Product Database lists Mounjaro, a tirzepatide prescription product, as approved. Its authorization, manufacturing controls, and clinical data apply to that regulated product. They do not transfer automatically to material from another supplier, even when the same molecule name appears on the label.

For research material, identity, amount, purity, sterility, endotoxin, residual solvents, and stability remain separate analytical questions. A receptor mechanism article cannot answer those batch-specific quality questions.

Bottom line

Tirzepatide is best understood as an engineered, long-acting peptide with activity at two incretin receptors. Its pharmacology is more specific than the phrase dual agonist implies: studies describe GIPR-favoured engagement and GLP-1R signalling bias. Human trials demonstrate outcomes for the regulated medicine, while the exact biological contribution of each receptor and each signalling feature is still being investigated.

Editorial standard: Sources were checked against the linked publication, regulator, or official product record. Evidence levels are identified in the text, and claims are limited to the material and research model actually studied.